Strong, consistent IP protections throughout U.S. history enabled the creation of innovative and useful technologies that we use regularly today. From entertainment to housework, every aspect of our lives has benefited greatly from IP, as shown by these historical examples from the month of August: 1960: On August 23, Peter Goldmark received a patent for […]
This Month in IP: August 2025 Read More »
August Highlights: Setting the Record Straight on the DOJ/FTC Listening Sessions The Department of Justice and Federal Trade Commission recently hosted listening sessions on “Lowering Americans’ Drug Prices Through Competition.” While aimed at exploring ways to expand generic and biosimilar availability, the sessions amplified misleading claims about the patent system — such as allegations of
C4IP Coalition Updates: August 2025 Read More »
In a new piece for Newsweek, Mircea Geoană, former NATO deputy secretary general and president of the Aspen Institute Romania, and Andrei Iancu, C4IP co-chair and former USPTO Director, warn that protecting intellectual property (IP) is not merely a trade issue, but a national security imperative. Strong and enforceable IP rights give innovators the confidence
In a piece published by Newsweek, C4IP Board Member and former U.S. Ambassador to China Gary Locke explains how, even as Chinese companies debut world-class technologies — like BYD’s lightning-quick EV charger and DeepSeek’s powerful AI model — some Chinese businesses and leaders are undermining the international agreements that underpin global innovation. Locke points to
In a new Law360 op-ed, C4IP Board Member and former Federal Judge Kathleen O’Malley explains why Congress should advance bipartisan reforms that would strengthen America’s patent system and protect innovation. She points to three bills as critical starting points. The Patent Eligibility Restoration Act would restore clarity for patent eligibility in emerging high-tech fields like
WASHINGTON (August 19, 2025) — Recently, Senators Maggie Hassan (D-NH) and Josh Hawley (R-MO) introduced the Medication Affordability and Patent Integrity Act, S. 2658, which would mandate that life sciences innovators submit extensive and often confidential information related to drug approval to the U.S. Patent and Trademark Office (USPTO). The bill would also require companies
In recent months, federal policymakers have renewed calls for “Most-Favored-Nation” (MFN) drug pricing, which would tie the price of medicines in the United States to the lowest prices paid in similarly wealthy foreign countries. The policy is well-meaning and directed at a real problem: foreign countries free-ride off of American-supported innovation by implementing policies that
